- Differential Diagnosis
Drug Information for FUROSEMIDEINJECTION, USP40 mg/mL (10 mg/mL) (McKesson Packaging Services Business unit of McKesson Corporation): OVERDOSAGE
- CLINICAL PHARMACOLOGY
- INDICATIONS AND USAGE
- ADVERSE REACTIONS
- HOW SUPPLIED
- PACKAGE DISPLAY PANEL
- External Links Related to FUROSEMIDEINJECTION, USP40 mg/mL (10 mg/mL) (McKesson Packaging Services Business unit of McKesson Corporation)
The principal signs and symptoms of overdose with furosemide are dehydration, blood volume reduction, hypotension, electrolyte imbalance, hypokalemia and hypochloremic alkalosis, and are extensions of its diuretic action.
The acute toxicity of furosemide has been determined in mice, rats and dogs. In all three, the oral LD50 exceeded 1000 mg/kg body weight, while the intravenous LD50 ranged from 300 to 680 mg/kg. The acute intragastric toxicity in neonatal rats is 7 to 10 times that of adult rats.
The concentration of furosemide in biological fluids associated with toxicity or death is not known. Treatment of overdosage is supportive and consists of replacement of excessive fluid and electrolyte losses. Serum electrolytes, carbon dioxide level and blood pressure should be determined frequently. Adequate drainage must be assured in patients with urinary bladder outlet obstruction (such as prostatic hypertrophy).
Hemodialysis does not accelerate furosemide elimination.
- Drug Information Provided by National Library of Medicine (NLM).